Clinical Analysis of Efficacy and Safety for FK506 after Renal Transplantation.
- Author:
Bum Soo KIM
1
;
Song Cheol KIM
;
Tae Hee KIM
;
Duck Jong HAN
Author Information
1. Department of Surgery, Ulsan University College of Medicine and Asan Medical Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Tacrolimus (FK506);
Cyclosporin;
Acute rejection;
Infection;
Graft survival
- MeSH:
Allografts;
Cyclosporine;
Graft Survival;
Humans;
Immunosuppression;
Incidence;
Kidney Transplantation*;
Living Donors;
Retrospective Studies;
Tacrolimus*;
Tissue Donors;
Transplants
- From:The Journal of the Korean Society for Transplantation
2002;16(1):76-83
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The introduction of tacrolimus (FK506) has increased the choice of immunosuppressive therapies in renal transplantation. METHODS: We retrospectively reviewed allograft patients who had been transplanted from Jan 1998 to May 2000 in FK506 group (n=57) and CsA group (n=300) to analyze renal graft outcomes and compared its effect with that of cyclosporin (CsA). RESULTS: There were significant differences in type of donor and HLA mismatches. Renal function in FK506 was similar to CsA group. FK506 group (n=57) was equivalent to CsA (n=300) group in biopsy-proven rejection and clinical rejection including biopsy-proven rejection, respectively (10.5%, 24.6% in FK506 group and 12.3%, 18.7% in CsA group). One year-graft survival of living donor did not show significant difference between two groups (FK506 vs. CsA: 94.44% vs. 96.75%, P=0.5557). The incidence of infection in FK506 (15.8%) group is similar to that in CsA (20%). But, death due to infectious complications was more prevalent in FK506 group (5.7%), compared with CsA group (0.7%). CONCLUSION: In summary, many significant benefits are associated with FK506 immunosuppression in renal transplantation with increasing experience of FK506, the incidence of infectious complications can be reduced.
